Global monoclonal antibodies market report 2017Chlue Reseach
McAbs has high targeting ability and can directly reach the diseased cells. Now McAbs are widely used in clinical practice with the unique advantages of reducing the damage of normal cells side effects.
The market share monoclonal antibody in global biopharmaceuticals has increased from 10% in 2000 to 42% in 2016.
It is the largest and fastest growing fine industry in the modern biopharmaceutical industry.
According to Chlue Research, the total sales of 52 kinds of McAbs approved by FDA were up to 99 billion US dollars in 2016, up 15% from 2015.
Content
McAbs Market
Biosimilars
Antineoplastic drugs
Autoimmune diseases
Ophthalmic remedy
PD-1 and PD-L1 McAbs
McAbs approved by FDA
Accuscript Pharmacovigilance Service - Literature Monitoring & Social Media D...Ajay Francis Christopher
- Global (via Embase & PubMed), Local journal & Social Media Literature Search
- Social Media Data mining (sentiment analysis of drugs)
- Review of literature search hits relevant for AE reporting/safety information
- Developing ready-to-use ICSR narratives
- QC of ICSRs.
Competition in the Food Sector: Issues Arising in the Meat SectorOECD Governance
Presentation by Professor Steve McCorriston, Professor of Agricultural Economics at the University of Exeter’s Business School, United Kingdom, at the II Competition and Regulation Forum: “Reaching for market efficiency” which took place in Mexico on 9-10 January 2018. Further information is available at www.oecd.org/gov/regulatory-policy/.
Global Generic Pharmaceutical Market - Qualitative and Quantitative AnalysisAiswariya Chidambaram
This report was presented at the Pharma Tech 2013 Conference - India A Game Changer in the Pharma Industry at Ahmedabad, India in December 2013. The presentation highlights the overview of the global generic pharmaceuticals market, with particular focus on the key market trends and challenges by therapeutic areas and geographies including the U.S, EU and India. List of key blockbuster drugs scheduled to lose patent protection between 2010 and 2020 have been included. Additionally impact of regulation on generic drugs by region and strategic recommendations for the success of market participants are also covered in this report.
Evolving Regulation of Biosimilars and Update on Generic Drug RegulationMichael Swit
Presentation to the Annual Educational Conference, jointly sponsored by the Orange County Regulatory Affairs (OCRA) Discussion Group and FDA, in June 2009, with a focus on:
Biosimilars
Overview of Current Situation in Europe
Regulatory and Scientific Issues
Product Development Issues
U.S. Legislative Options
Waxman Bill
Eshoo
Generic Drugs – Update on U.S. Initiatives
Question Based Review (QBR)
User Fees
Patent Settlements
This presentation by Valérie Paris, Senior Health Policy Analyst, OECD, was made during the discussion “Excessive prices in pharmaceutical markets" held at the OECD Competition Open Day on 27 February 2019. More documents and presentations on this topic can be found at oe.cd/comp-open-day-19.
Global monoclonal antibodies market report 2017Chlue Reseach
McAbs has high targeting ability and can directly reach the diseased cells. Now McAbs are widely used in clinical practice with the unique advantages of reducing the damage of normal cells side effects.
The market share monoclonal antibody in global biopharmaceuticals has increased from 10% in 2000 to 42% in 2016.
It is the largest and fastest growing fine industry in the modern biopharmaceutical industry.
According to Chlue Research, the total sales of 52 kinds of McAbs approved by FDA were up to 99 billion US dollars in 2016, up 15% from 2015.
Content
McAbs Market
Biosimilars
Antineoplastic drugs
Autoimmune diseases
Ophthalmic remedy
PD-1 and PD-L1 McAbs
McAbs approved by FDA
Accuscript Pharmacovigilance Service - Literature Monitoring & Social Media D...Ajay Francis Christopher
- Global (via Embase & PubMed), Local journal & Social Media Literature Search
- Social Media Data mining (sentiment analysis of drugs)
- Review of literature search hits relevant for AE reporting/safety information
- Developing ready-to-use ICSR narratives
- QC of ICSRs.
Competition in the Food Sector: Issues Arising in the Meat SectorOECD Governance
Presentation by Professor Steve McCorriston, Professor of Agricultural Economics at the University of Exeter’s Business School, United Kingdom, at the II Competition and Regulation Forum: “Reaching for market efficiency” which took place in Mexico on 9-10 January 2018. Further information is available at www.oecd.org/gov/regulatory-policy/.
Global Generic Pharmaceutical Market - Qualitative and Quantitative AnalysisAiswariya Chidambaram
This report was presented at the Pharma Tech 2013 Conference - India A Game Changer in the Pharma Industry at Ahmedabad, India in December 2013. The presentation highlights the overview of the global generic pharmaceuticals market, with particular focus on the key market trends and challenges by therapeutic areas and geographies including the U.S, EU and India. List of key blockbuster drugs scheduled to lose patent protection between 2010 and 2020 have been included. Additionally impact of regulation on generic drugs by region and strategic recommendations for the success of market participants are also covered in this report.
Evolving Regulation of Biosimilars and Update on Generic Drug RegulationMichael Swit
Presentation to the Annual Educational Conference, jointly sponsored by the Orange County Regulatory Affairs (OCRA) Discussion Group and FDA, in June 2009, with a focus on:
Biosimilars
Overview of Current Situation in Europe
Regulatory and Scientific Issues
Product Development Issues
U.S. Legislative Options
Waxman Bill
Eshoo
Generic Drugs – Update on U.S. Initiatives
Question Based Review (QBR)
User Fees
Patent Settlements
This presentation by Valérie Paris, Senior Health Policy Analyst, OECD, was made during the discussion “Excessive prices in pharmaceutical markets" held at the OECD Competition Open Day on 27 February 2019. More documents and presentations on this topic can be found at oe.cd/comp-open-day-19.
Research project Trying to find the hidden patterns behind Long term Points – interesting / surprising / unexpected
How do companies set or predict prices. What would you do?
A guess could be based on a particular competitor, or a key supplier, or an average, but it is still at heart a guess
Trend lines can be added to what data you have, but often more than one line can be fitted to the same trend, and if you only have a few months of post patent generic prices, many trends could be fitted to the same data – each one a guess.
The price went up, as it was following a hidden pattern, not immediately obvious to the uninformed
Trend lines can be added to what data you have, but often more than one line can be fitted to the same trend, and if you only have a few months of post patent generic prices, many trends could be fitted to the same data – each one a guess.
Trend lines can be added to what data you have, but often more than one line can be fitted to the same trend, and if you only have a few months of post patent generic prices, many trends could be fitted to the same data – each one a guess.
But sometimes they don't
The range of decline curves possible is very wide
Information revolution Bill gates Email Design around the planet Ebay Lack of science in one area of pharma – pricing Aunt story
The range of decline curves possible is very wide
Each of the 100+ decline curves we looked at was based on a pattern
Each could be modelled
Each could be connected with the underlying factors
Even the rises in price due to availability and price could be predicted
Even the rises in price due to availability and price could be predicted
The range of decline curves possible is very wide
The range of decline curves possible is very wide
Patterns are complex but predictable Not as complicated as shares But pharmaceuticals is an island – doesn't pick up techniques from other industries easily Why has no one done it before – not enough pricing history Norton healthcare SPSS experience
So the method works Will get better as more examples are analysed Sugar traders / stocks and shares But bounces still an issue ….. But what about other markets
Nothing is new But pharma is still left with vulnerability in those companies that don’t take this on board No reason why techniques won’t work in other states